What is Thymosin Alpha-1?

Thymosin Alpha-1 (Ta1) is a naturally occurring peptide involved in immune regulation, particularly the function of T-cells. It is marketed as the prescription medicine thymalfasin in some countries.

What does research suggest about Thymosin Alpha-1?

Research indicates Thymosin Alpha-1 modulates immune activity, including effects on T-cell function. Clinical evidence supports the specific indications for which it is approved in the countries where it is registered, with additional immune effects documented in preclinical studies.

Is Thymosin Alpha-1 approved?

It is approved as a medicine (thymalfasin) in some countries for specific indications, but it is not universally approved. In many regions it has no approved status and is sold only as an unverified research material.

Is Thymosin Alpha-1 safe?

Where it is approved, it is prescribed and monitored by clinicians. Use of unregulated research-market products is not verified for safety, purity, or identity, and falls outside any approved medical framework.

What are the side effects of Thymosin Alpha-1?

Injection-site reactions have been reported. A full safety profile is best established within the approved medical settings where the peptide is prescribed and monitored; research-market use is unverified.

What is the legal status of Thymosin Alpha-1?

Legal status varies by country. It is a registered prescription medicine in some jurisdictions and unapproved in others. Commercial availability is restricted, and this page is educational information rather than legal or medical advice.

Why is Thymosin Alpha-1 an approved medicine in some countries but not others?

Regulatory approval is granted country by country, and each agency weighs its own review of the clinical evidence for specific indications. Thymalfasin was registered in several countries (often for viral hepatitis and immune-related uses) where regulators judged the data sufficient for those indications, while other agencies — including the US FDA — have not approved it for general use. Approval elsewhere does not mean a product sold on the research market is the same, quality-controlled medicine.

Is Thymosin Alpha-1 the same as "thymosin beta-4" or TB-500?

No. They are different peptides that happen to share the "thymosin" name because both were originally identified in thymic tissue fractions. Thymosin alpha-1 is a 28-amino-acid peptide associated with immune regulation, whereas thymosin beta-4 (the parent of the TB-500 fragment) is a separate, longer peptide studied mainly in tissue-repair contexts. The shared prefix is a historical naming artifact, not a sign they do the same thing.

Why does Thymosin Alpha-1 come up so often in "immune support" discussions?

Because it is one of the few peptides in these conversations that is an actually approved medicine somewhere, its name carries more perceived legitimacy than purely research-stage compounds. That regulatory history, combined with its documented role in immune regulation, makes it a frequent reference point. Being approved for narrow indications in some countries is not the same as being an evidence-backed general "immune booster," and this page is educational rather than a recommendation to use it.

Where can I buy Thymosin Alpha-1 and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Immune

Buy Thymosin Alpha-1 – Vendors, Prices, Testing and Evidence

Buy Thymosin Alpha-1

Also known as: Ta1 · Thymalfasin

Evidence grade B — Human, limited

Short answer

An immune-modulating peptide approved in some countries for specific conditions.

Where can you buy Thymosin Alpha-1?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

Thymosin Alpha-1 is a peptide involved in immune regulation, marketed as thymalfasin in some regions.

What is not established?

Clinical evidence exists for specific approved indications in the countries where it is registered.

Safety

Where approved it is prescribed and monitored; research-market use is unverified.

Regulatory status

Approved as a medicine (thymalfasin) in some countries for specific indications; not universally approved.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Vendor comparison

Buy Thymosin Alpha-1: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	Thymosin Alpha-1 research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

Thymosin Alpha-1 research product

Code PEPTIDES10 −10% · discount code details

What is it?

Thymosin Alpha-1 is a peptide involved in immune regulation, marketed as thymalfasin in some regions.

Research and evidence

Thymosin Alpha-1 (often written Ta1 and marketed under the international nonproprietary name thymalfasin) is a 28-amino-acid peptide that plays a role in regulating the immune system. It is derived from the thymus gland, the organ where T-cells mature, and is one of the most studied peptides in the immune-modulation category. Unlike many peptides discussed online, Thymosin Alpha-1 has a genuine clinical track record: it is approved as a prescription medicine in a number of countries for specific indications, though it is not universally approved worldwide.

Research interest in Thymosin Alpha-1 centers on its ability to influence T-cell function and broader immune signaling. Where it has been formally studied and registered as thymalfasin, clinical evidence supports its use for the particular conditions for which it was approved in those jurisdictions. Preclinical and laboratory work has further documented its immune-modulating activity, helping to characterize how the peptide interacts with immune cells. This combination of approved-drug status in some regions and an established mechanistic profile is why Thymosin Alpha-1 carries a comparatively stronger evidence rating than many research-only peptides — while still falling short of universal regulatory acceptance.

It is important to distinguish between the two very different contexts in which Thymosin Alpha-1 appears. In the countries where it is a registered medicine, it is prescribed, dosed, and monitored by clinicians for defined uses. In the unregulated "research chemical" or wellness market, products labeled as Thymosin Alpha-1 are not verified for identity, purity, or safety, and their use falls outside any approved medical framework. This page is an educational reference summarizing what the science indicates; it is not medical advice, and it does not provide dosing, protocols, or sourcing guidance. Anyone considering Thymosin Alpha-1 in a medical context should consult a qualified healthcare professional.

Evidence grade: B

Clinical evidence exists for specific approved indications in the countries where it is registered. Immune-modulating effects documented preclinically.

Human evidence

Clinical evidence exists for specific approved indications in the countries where it is registered.

Animal and preclinical evidence

Immune-modulating effects documented preclinically.

Proposed mechanisms

Immune modulation, including effects on T-cell function

Safety concerns and known side effects

Where approved it is prescribed and monitored; research-market use is unverified.

Injection-site reactions reported

Regulatory status

Approved as a medicine (thymalfasin) in some countries for specific indications; not universally approved.

Thymosin Alpha-1 research timeline

1960s–1970s
Research on thymic extracts (thymosin fraction 5) by Allan Goldstein and colleagues identifies immune-active peptides from the thymus gland.
Late 1970s
Thymosin alpha-1 is isolated from that fraction and its 28-amino-acid sequence is characterized, distinguishing it as a discrete immune-modulating peptide.
1980s–1990s
The synthetic version (thymalfasin) is developed and enters human clinical trials, largely for chronic viral hepatitis and as an adjunct in immune-compromised settings.
1990s–2000s
Thymalfasin gains regulatory approval as a medicine in a number of countries (for example for hepatitis B and C and certain immune indications), while remaining unapproved in others including the US.
Early 2020s
The compound is examined in exploratory clinical research during the COVID-19 pandemic for possible immune-supportive roles; results were mixed and did not establish broad new approvals.

Frequently asked questions about Thymosin Alpha-1

What is Thymosin Alpha-1?: Thymosin Alpha-1 (Ta1) is a naturally occurring peptide involved in immune regulation, particularly the function of T-cells. It is marketed as the prescription medicine thymalfasin in some countries.
What does research suggest about Thymosin Alpha-1?: Research indicates Thymosin Alpha-1 modulates immune activity, including effects on T-cell function. Clinical evidence supports the specific indications for which it is approved in the countries where it is registered, with additional immune effects documented in preclinical studies.
Is Thymosin Alpha-1 approved?: It is approved as a medicine (thymalfasin) in some countries for specific indications, but it is not universally approved. In many regions it has no approved status and is sold only as an unverified research material.
Is Thymosin Alpha-1 safe?: Where it is approved, it is prescribed and monitored by clinicians. Use of unregulated research-market products is not verified for safety, purity, or identity, and falls outside any approved medical framework.
What are the side effects of Thymosin Alpha-1?: Injection-site reactions have been reported. A full safety profile is best established within the approved medical settings where the peptide is prescribed and monitored; research-market use is unverified.
What is the legal status of Thymosin Alpha-1?: Legal status varies by country. It is a registered prescription medicine in some jurisdictions and unapproved in others. Commercial availability is restricted, and this page is educational information rather than legal or medical advice.
Why is Thymosin Alpha-1 an approved medicine in some countries but not others?: Regulatory approval is granted country by country, and each agency weighs its own review of the clinical evidence for specific indications. Thymalfasin was registered in several countries (often for viral hepatitis and immune-related uses) where regulators judged the data sufficient for those indications, while other agencies — including the US FDA — have not approved it for general use. Approval elsewhere does not mean a product sold on the research market is the same, quality-controlled medicine.
Is Thymosin Alpha-1 the same as "thymosin beta-4" or TB-500?: No. They are different peptides that happen to share the "thymosin" name because both were originally identified in thymic tissue fractions. Thymosin alpha-1 is a 28-amino-acid peptide associated with immune regulation, whereas thymosin beta-4 (the parent of the TB-500 fragment) is a separate, longer peptide studied mainly in tissue-repair contexts. The shared prefix is a historical naming artifact, not a sign they do the same thing.
Why does Thymosin Alpha-1 come up so often in "immune support" discussions?: Because it is one of the few peptides in these conversations that is an actually approved medicine somewhere, its name carries more perceived legitimacy than purely research-stage compounds. That regulatory history, combined with its documented role in immune regulation, makes it a frequent reference point. Being approved for narrow indications in some countries is not the same as being an evidence-backed general "immune booster," and this page is educational rather than a recommendation to use it.
Where can I buy Thymosin Alpha-1 and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Immune support contextApproved use vs research use

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10